Monthly Archives: September 2017
The Perils of Competitive Speed Eating!
3D Cross-Sectional Imaging of the Inflamed Gut With Light Sheet Fluorescence Microscopy for Translational Research in IBD
The precise pathogenesis of inflammatory bowel diseases (IBD) such as Crohn’s disease (CD) or ulcerative colitis (UC) is still unclear. However, novel treatment options have become available recently1,2 and several further compounds might soon help t… Continue reading
3D Cross-Sectional Imaging of the Inflamed Gut With Light Sheet Fluorescence Microscopy for Translational Research in IBD
The precise pathogenesis of inflammatory bowel diseases (IBD) such as Crohn’s disease (CD) or ulcerative colitis (UC) is still unclear. However, novel treatment options have become available recently1,2 and several further compounds might soon help t… Continue reading
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease is a comprehensive review of the use of anti-tumor necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD). The book includes a preface and 35 chapters, which can … Continue reading
Easing Concerns About the Low FODMAP Diet in Patients With Irritable Bowel Syndrome
Dietary management makes sense in patients with irritable bowel syndrome, because food is a major inducer of symptoms, and dietary manipulation empowers patients to influence the outcome of their disorder. It is not surprising, therefore, that the arri… Continue reading
Progress in PD-1–based Immunotherapy: New Mechanistic Insight May Provide Expanded Hope for Application to Colon and Gastrointestinal Cancers
Kamphorst AO, Wieland A, Tahseen Nasti T, et al. Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent. Science 2017;355:1423-1427. Continue reading
ROCKing the Field of Intestinal Fibrosis or Between a ROCK and a Hard Place?
Intestinal fibrosis remains one of the largest clinical challenges in the field of inflammatory bowel diseases.1 More than one-half of the patients with Crohn’s disease develop clinically apparent fibrostenosis throughout their disease course, leadin… Continue reading
Risk for Hepatocellular Carcinoma After Hepatitis C Virus Antiviral Therapy With Direct-acting Antivirals: Case Closed?
The development of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection was well-received by patients and physicians, as viral clearance is associated with improved liver-related and overall survivals.1,2 Despite this … Continue reading
Covering the Cover
In a large cohort of patients with chronic hepatitis C infection, sustained virologic response after direct-acting antiviral therapy lowered, but did not eliminate, the risk of hepatocellular carcinoma. Continue reading